ISSN: 2572-4118

Breast Cancer: Current Research
Open Access

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)
  • Short Communication   
  • Breast Can Curr Res 2023, Vol 8(5): 5
  • DOI: 10.4172/2572-4118.1000215

Treatment of HER2-Positive Metastatic Breast Cancer with Lymphangitic Carcinomatosis Using Triple HER2-Blockade

Yuka Ozaki*
Department of Breast Oncology, Japan
*Corresponding Author : Yuka Ozaki, Department of Breast Oncology, Japan, Email: Yozaki134@gmail.com

Received Date: Oct 01, 2023 / Published Date: Oct 30, 2023

Abstract

Lymphangitic carcinomatosis (LC) represents a rare and challenging manifestation of metastatic breast cancer, often associated with poor prognosis and limited treatment options. HER2-positive breast cancer subtype accounts for a significant proportion of metastatic cases, and targeted therapies, such as trastuzumab and pertuzumab, have demonstrated clinical benefit. However, patients with LC require alternative strategies to address the unique challenges posed by this aggressive form of metastasis. We present a case report of a 48-year-old female diagnosed with HER2-positive metastatic breast cancer complicated by LC. In this report, we detail the comprehensive treatment approach utilizing a triple HER2-blockade regimen consisting of lapatinib, trastuzumab, and pertuzumab. The patient’s clinical course, radiographic findings, and treatment response are discussed. The patient exhibited clinical improvement, with reduced dyspnea, stabilization of her pulmonary symptoms, and improved quality of life after initiating the triple HER2-blockade regimen. Radiographic assessments revealed decreased tumor burden within the lung lymphatics. The treatment was generally well-tolerated, with manageable side effects. This case report highlights the potential of a triple HER2-blockade strategy in managing HER2-positive metastatic breast cancer with LC. While further research and larger clinical trials are necessary to confirm the efficacy of this approach, our case suggests that it may offer a promising option for patients with limited treatment choices in this challenging clinical scenario. The findings underscore the importance of individualized treatment plans and ongoing research in optimizing therapies for metastatic breast cancer, particularly in cases complicated by LC.

Citation: Ozaki Y (2023) Treatment of HER2-Positive Metastatic Breast Cancerwith Lymphangitic Carcinomatosis Using Triple HER2-Blockade. Breast Can CurrRes 8: 215. Doi: 10.4172/2572-4118.1000215

Copyright: © 2023 Ozaki Y. This is an open-access article distributed under theterms of the Creative Commons Attribution License, which permits unrestricteduse, distribution, and reproduction in any medium, provided the original author andsource are credited.

Top